A recent study illustrated the upregulation of TRA2B targeted by miR-335 could promote the cell proliferation of lung cancer [64], another study even verified the TRA2B-DNAH5 fusion as a novel oncogenic driver in LUSC independent to LUAD [65]. Here, TRA2B is linked to lung carcinoma.